New radiotherapy treatment promises better cure rates with fewer side effects
Video: A SABR radiotherapy session in real time.
The SABR Prostate Trial
PCF and our partners are funding a national clinical trial to demonstrate the benefits of Stereotactic Ablative Body Radiotherapy (SABR).
The trial, which is taking place at nine Canadian cancer centres (and is part of a large-scale international trial called PACE), comes after early research indicated that SABR may deliver better cure rates with fewer side effects than the standard radiotherapy protocol.
With SABR, radiation sessions are reduced from 39 to just five.
Here are just a few of the benefits being tested in this trial:
Reduced Side Effects in Sexual and Urinary Functioning
96% of SABR patients retain normal sexual function compared to baseline.
High Rates of Remission Five Years After Treatment
99% for low-risk patients and 93% for intermediate-risk patients.
Lower Treatment Cost Per Patient
Cost for 5-session SABR is $1,470 vs. $6,987 for 39-session EBRT.
Download the SABR
Prostate Trial Infographic
Read about all the SABR benefits demonstrated in preliminary research.
How to get the SABR treatment
The SABR Prostate Trial completed its accrual on December 31, 2017. We are no longer looking for men to participate in the study.
If you think you might benefit from SABR, please contact your oncologist. Currently, Sunnybrook Health Sciences Centre in Toronto is offering SABR to patients who qualify for the treatment.
We anticipate that the cancer centres that were trained to participate in the SABR Trial may offer the treatment in the near future. We will post updates as they become available